期刊文献+

临床药师参与1例人工肝术后下肢深静脉血栓病例的临床实践 被引量:3

Clinical Practice of Clinical Pharmacist Participating in a Case of Deep Venous Thrombosis of Lower Limb After Artificial Liver
原文传递
导出
摘要 目的通过临床药师参与1例人工肝术后下肢深静脉血栓病例的临床治疗实践,探讨临床药师在治疗中所起的作用。方法临床药师通过查阅指南、专家共识、文献资料,分析人工肝术后下肢深静脉血栓形成的原因,预防措施以及参与制定个体化抗凝治疗方案、药学监护及用药教育。结果临床医师与药师共同制定华法林抗凝治疗方案,临床药师对患者进行药学监护、用药教育,用药过程未収生不良反应,患者熟练掌握华法林治疗注意事项,依从性良好。结论临床药师协助临床医师制定个体化的抗凝治疗方案,做好药学监护、用药教育,保障治疗的安全性、有效性。 OBJECTIVE To study the role of clinical pharmacist in the treatment of a case deep venous thrombosis of lower limb after artificial liver by clinical practice.METHODS Based on guidelines,experted consensus and literatures,clinical pharmacist analyzed the causes of deep venous thrombosis of lower limb after artificial liver,preventive measures and participated in individualized anticoagulant therapy,pharmaceutical care and medication education.RESULTS The anticoagulant therapy of warfarin developed by clinician and clinical pharmacist cured the patient with no adverse drug reactions,and clinical pharmacist carried out pharmaceutical care,medication education.The patient master notice of warfarin and had good medication compliance.CONCLUSION Clinical pharmacist assist clinician to develop individualized anticoagulant therapy,carry out pharmaceutical care,medication education to ensure the safety and effectiveness of treatment.
作者 周婧 茹仁萍 陈娜 ZHOU Jing;RU Renping;CHEN Na(Department of Pharmacy,Xixi Hospital of Hangzhou,Hangzhou 310023,China;Department of Pharmacy,First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310003,China)
出处 《中国现代应用药学》 CAS CSCD 北大核心 2020年第10期1224-1228,共5页 Chinese Journal of Modern Applied Pharmacy
关键词 人工肝 下肢深静脉血栓 抗凝治疗 artificial liver deep venous thrombosis of lower limb anticoagulant therapy
  • 相关文献

参考文献13

二级参考文献78

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:163
  • 2黄建荣.生物型人工肝用肝细胞源研究现状及展望[J].中华肝脏病杂志,2007,15(3):217-218. 被引量:7
  • 3预防骨科大手术深静脉血栓形成指南(草案)[J].中华骨科杂志,2007,27(10):790-792. 被引量:113
  • 4Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 5Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 6Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 7Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 8Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 9Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 10Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.

共引文献2217

同被引文献32

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部